Publications and Investor Resources

UTILITY therapeutics is a biotechnology company focused on the US development and commercialization of 2 European-approved antibiotics, pivmecillinam and mecillinam, for the treatment of urinary tract infections.

Our approach is to identify exceptional candidates who meet urgent needs and draw on our expertise to expedite approval and make new options available to healthcare professionals and patients as quickly as possible.

News and Updates

Nothing found.

Access key articles and publications about antibiotic resistance in UTIs and treatment guidelines and options

European Association of Urology Urological Infections Guidelines >>
Presented at the EAU Annual Congress, Amsterdam, the Netherlands, 2020.
Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria >>
Dewer S, et al. J Antimicrob Chemother. 2014;69(2):303-308.
The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017 >>
Critchley IA, et al. PLoS One. 2019;14(12):e0220265.
International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases >>
Gupta K, et al. Clin Infect Dis. 2011;52(5):e103-e120.

Investor Resources

Investor Relations Contact

UTILITY therapeutics at info@utilitytherapeutics.com

Contact Us

CONNECT